RenovoRx Inc

RenovoRx CFO’s zero‑cost RSU grant signals insider confidence amid rising trial data, market rally, and positive social‑media buzz—boosting investor outlook.

RenovoRx insider purchases reveal strategic private placement, revenue‑triggered warrants, and strong leadership confidence ahead of pancreatic cancer milestone.

RenovoRx insider buying shows exec confidence in its targeted chemo pipeline, private placement, and warrants, hinting at long‑term upside amid market volatility.